Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QHRD106 in acute ischemic stroke
NCT07396337Phase 2Recruiting
- Sponsor
- Changzhou Qianhong Biopharma Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
A Phase 2 trial of QHRD106 in ischemic stroke, sponsored by Changzhou Qianhong Biopharma Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
QHRD106
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07396337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396337.